Caicun Zhou - Concepedia

Author

Caicun Zhou

Also Known As

C Zhou, C. Zhou, C.-C. Zhou, CAICUN ZHOU, Cai-Cun Zhou, Cai-cun ZHOU, Cai-cun Zhou, CaiCun Zhou, Caicun ZHOU, Caicun Zhou

385

Publications

10.7K

Citations

H-Index

Concepts

All Affiliations

Shanghai Pulmonary Hospital Tongji University Henan Cancer Hospital Zhejiang Cancer Hospital Hunan Cancer Hospital

About

Caicun Zhou is an author at Shanghai Pulmonary Hospital specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	50	2.6K
2	Health Sciences	14	19	841
3	Cell Biology	9	9	406
4	Allergy	1	1	65
5	Diagnostic Sciences	1	1	14

Caicun Zhou

114

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer Fengying Wu, Jue Fan, Yayi He, Nature Communications	2021	759
Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases Daniel B. Costa, Alice T. Shaw, Sai‐Hong Ignatius Ou, Journal of Clinical Oncology	2015	603
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Journal of Clinical Oncology	2015	381
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Jie Wang, Caicun Zhou, Wenxiu Yao, The Lancet Oncology OncologyPharmacologyBronchial NeoplasmImmune Checkpoint InhibitorFirst-line Treatment	2022	361
Lung cancer in China: current and prospect Fengying Wu, Lei Wang, Caicun Zhou Current Opinion in Oncology	2020	308
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions Caicun Zhou, Kejing Tang, Byoung Chul Cho, New England Journal of Medicine	2023	301
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12) Caicun Zhou Journal of Thoracic Oncology OncologyMedicineClinical TrialsMetastatic Squamous NsclcFirst-line Treatment	2021	293
LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, Hui Yu, Leslie Rozeboom, Journal of Thoracic Oncology	2017	269
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, The Lancet Respiratory Medicine MedicineRandomised Phase 3ImmunologyPathologyAlectinib Versus Crizotinib	2019	268
Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer Tony Mok, Yi‐Long Wu, Chong‐Jen Yu, Journal of Clinical Oncology	2009	220

Page 1